Manufacturer defends the drugBMJ 1996; 313 doi: https://doi.org/10.1136/bmj.313.7067.1263a (Published 16 November 1996) Cite this as: BMJ 1996;313:1263
- P N Longthorne
- Medical director Schering Health Care, Burgess Hill RH15 9NE
EDITOR,—It was disappointing to read Peter Harvey's letter dismissing the value of interferon beta 1b in the treatment of patients with relapsing-remitting multiple sclerosis.1 Harvey takes no account of the results of controlled clinical trials showing a significant reduction in severity and frequency of relapses (up to 30–50%),2 3 with the most severe cases benefiting most, or of the accumulating data showing that generally there …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial